Déjà Vu: Revived Mifepristone Case Puts FDA And Pharma At Risk Again

 
• By Sarah Karlin-Smith
  
Three pill bottles of mifepristone.
Litigation over abortion pill mifepristone once again puts the entire FDA approval process at risk. (Shutterstock)

More from Litigation

More from Legislation